Interferon-α treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan
Article first published online: 7 APR 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Munksgaard
Volume 28, Issue 9, pages 1288–1297, October 2008
How to Cite
Hsu, H.-Y., Tsai, H.-Y., Wu, T.-C., Chiang, C.-L., Ni, Y.-H., Chen, P.-J. and Chang, M.-H. (2008), Interferon-α treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver International, 28: 1288–1297. doi: 10.1111/j.1478-3231.2008.01746.x
- Issue published online: 5 SEP 2008
- Article first published online: 7 APR 2008
- Received 20 November 2007Accepted 24 February 2008
- chronic hepatitis B;
- interferon-α therapy;
- young adults
Background/Aims: The short- and long-term benefits of interferon (IFN)-α therapy in young patients with chronic hepatitis B (CHB) acquiring infection perinatally or during early childhood have been questioned.
Methods: Twenty-one Taiwanese hepatitis B envelope antigen (HBeAg)-positive CHB patients aged 1.8–21.8 years (median 14.0 years) with alanine aminotransferase (ALT)>80 IU/L at entry were enrolled for IFN-α therapy. They received IFN-α therapy with a dose of 3 MU/m2/day three times a week for 24 weeks. A control group included untreated 21 CHB patients closely matched for gender, age, duration of ALT >80 IU/L and HBeAg status. All 42 patients were prospectively followed for 6.5–12.5 years after the end of therapy.
Results: The cumulative rate of virological response [anti-HBe seroconversion and serum hepatitis B virus (HBV)-DNA <105 copies/ml] was not different between the IFN-treated patients and control patients at 1 year (41 vs 44%) and at 6 years (88 vs 89%) after stopping treatment. Serum hepatitis B surface antigen loss occurred in two (9.5%) treated patients and in one (4.8%) control patient. Patients with a successful treatment response (anti-HBe seroconversion, HBV-DNA <102 copies/ml and ALT normalization at 1 year after stopping treatment) were younger than those without a successful response (P=0.03). A lower pretreatment serum HBV-DNA level (<2 × 108 copies/ml) is not only a significant factor to predict successful treatment response (P=0.008) but also has a beneficial effect on the long-term cumulative rate of virological response in IFN-treated patients (P=0.021), but not in control patients. Genotype difference or emergence of a precore stop codon mutant before treatment was not predictive for HBeAg clearance.
Conclusion: For young CHB patients in Taiwan with infection occurring perinatally or in early childhood, the real advantage of IFN-α therapy was not observed. IFN-α therapy showed a beneficial effect on short- and long-term virological outcomes only in those with a lower pretreatment serum HBV-DNA level.